Insider Selling: Teladoc Health (NYSE:TDOC) CEO Sells $152,243.19 in Stock

Teladoc Health, Inc. (NYSE:TDOC) CEO Charles Divita III sold 27,731 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total value of $152,243.19. Following the sale, the chief executive officer owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. This represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Teladoc Health Stock Up 0.3%

Shares of NYSE TDOC opened at $5.38 on Friday. Teladoc Health, Inc. has a 12-month low of $4.40 and a 12-month high of $9.77. The stock’s fifty day simple moving average is $5.62 and its two-hundred day simple moving average is $7.05. The stock has a market capitalization of $958.88 million, a PE ratio of -4.71 and a beta of 2.13. The company has a current ratio of 2.77, a quick ratio of 2.67 and a debt-to-equity ratio of 0.72.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. The firm had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The business’s revenue for the quarter was up .3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. As a group, analysts expect that Teladoc Health, Inc. will post -1.16 EPS for the current fiscal year.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates (improvements to Q1–Q4 2026, FY2026 and FY2027), which narrows expected losses and helps valuation/earnings outlook. Zacks Research coverage
• Positive Sentiment: Deutsche Bank upgraded TDOC to Buy, citing BetterHelp momentum, AI initiatives and international expansion — contributing to renewed analyst interest that can lift demand. Deutsche Bank upgrade
• Positive Sentiment: Coverage pieces highlight an earnings beat and strategic plans (BetterHelp, AI, international) that have put TDOC back on investors’ radar and supported recent short‑term gains. Valuation analysis
• Neutral Sentiment: Market notes point to volatility and short‑term moves relative to the broader market — useful context for traders but not a direct company catalyst. Market note
• Negative Sentiment: JPMorgan lowered its price target from $9 to $7 and assigned a “neutral” rating — a reduction in expected upside that can weigh on sentiment even though the new target still implies upside from current levels. JPMorgan note
• Negative Sentiment: Insider selling: CEO Charles Divita III sold 27,731 shares at ~$5.49 (disclosed in an SEC filing), reducing his stake by ~7% — a sell by the CEO that some investors may view negatively. SEC filing

Hedge Funds Weigh In On Teladoc Health

Institutional investors and hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its stake in shares of Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after buying an additional 2,810 shares during the last quarter. IFP Advisors Inc raised its position in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares in the last quarter. Aster Capital Management DIFC Ltd lifted its holdings in Teladoc Health by 101.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after acquiring an additional 2,425 shares during the period. International Assets Investment Management LLC acquired a new position in Teladoc Health in the fourth quarter valued at approximately $45,000. Finally, Bayforest Capital Ltd purchased a new stake in Teladoc Health in the 3rd quarter worth approximately $58,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on TDOC shares. Piper Sandler restated an “overweight” rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. TD Cowen reduced their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. JPMorgan Chase & Co. decreased their target price on shares of Teladoc Health from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday. Deutsche Bank Aktiengesellschaft upgraded shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Tuesday, March 10th. Finally, Wells Fargo & Company reduced their price target on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Teladoc Health presently has an average rating of “Hold” and an average price target of $7.72.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.